When Hope Lancaster Colquhoun was prescribed Mounjaro and instantly shed the pounds, the jab felt like a 'lifeline'. But her ...

GreensKeeper Asset Management, an investment management company, released its second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The Value Fund has reached the midpoint ...

Williams is not the first sportsperson to promote GLP-1 weight loss medication but she is the most high profile and easily ...

As the patent for semaglutide nears its end, Novo Nordisk's dominance in the weight-loss market is being challenged. The ...

Eli Lilly and Company is making headlines with a staggering 170% price increase for its weight-loss drug, Mounjaro, in the UK ...

Eli Lilly and Company (NYSE: LLY) is one of the best stocks to invest in for long-term growth. Eli Lilly and Company ...

The company raised its full-year revenue guidance from a range of $58 billion to $61 billion to a range of $60 billion to $62 ...

Can Novo Nordisk and Eli Lilly regain their former stock market glory? A lot is riding on next year's pills ...

The drug, which is estimated to be taken by up to 750,000 people, is one of the country's most popular weight loss and ...

Vivienne Joy runs a community of hundreds of weight loss jab users and said the increased cost of Mounjaro had 'created chaos ...

COMMENT: The monthly cost of a private prescription exceeding £300 from next month is worrying news for the half a million ...

Through innovation, cost discipline, legal action, and competitive pricing, Novo Nordisk has reasserted its leadership in the GLP-1 market. With a robust pipeline and global expansion, NVO is poised ...